Rachel L Navarra, PhD

2010-2016 Pharmacology and physiology Drexel University College of Medicine, Philadelphia, PA, United States 
 2016- Cell biology and neuroscience Rowan University School of Osteopathic Medicine 
"Rachel Navarra"
Mean distance: (not calculated yet)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Waterhouse BD, Navarra RL. (2018) The locus coeruleus-norepinephrine system and sensory signal processing: A historical review and current perspectives. Brain Research
Navarra RL, Waterhouse BD. (2018) Considering noradrenergically mediated facilitation of sensory signal processing as a component of psychostimulant-induced performance enhancement. Brain Research
Navarra RL, Clark BD, Gargiulo AT, et al. (2016) Methylphenidate Enhances Early Stage Sensory Processing and Rodent Performance of a Visual Signal Detection Task. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
Navarra RL, Clark BD, Zitnik GA, et al. (2013) Methylphenidate and atomoxetine enhance sensory-evoked neuronal activity in the visual thalamus of male rats. Experimental and Clinical Psychopharmacology. 21: 363-74
Kelly MP, Logue SF, Brennan J, et al. (2010) Phosphodiesterase 11A in brain is enriched in ventral hippocampus and deletion causes psychiatric disease-related phenotypes. Proceedings of the National Academy of Sciences of the United States of America. 107: 8457-62
Brennan JA, Graf R, Grauer SM, et al. (2010) WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: a novel dopamine D2 receptor partial agonist/serotonin reuptake inhibitor with preclinical antipsychotic-like and antidepressant-like activity. The Journal of Pharmacology and Experimental Therapeutics. 332: 190-201
Rotella DP, McFarlane GR, Greenfield A, et al. (2009) Tetrahydrocarbazole-based serotonin reuptake inhibitor/dopamine D2 partial agonists for the potential treatment of schizophrenia. Bioorganic & Medicinal Chemistry Letters. 19: 5552-5
Grauer SM, Pulito VL, Navarra RL, et al. (2009) Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. The Journal of Pharmacology and Experimental Therapeutics. 331: 574-90
See more...